Treatment of chronic neuropathic pain after surgery. Other chronic postprocedural pain
Conditions
Interventions
Intervention group: Injection of botulinum toxin type A (Masport) (BoNT/A) in an amount of 500 U in 5 or 10 ml of saline (5 or 10 IU/0.1 ml) will be administered subcutaneously based on the extent of
Sponsors
Tehran University of Medical Sciences
Eligibility
Sex/Gender
All
Age
19 Years to No maximum
Inclusion criteria
Inclusion criteria: male or female over 19 years old Suffering from neuropathic pain based on the DN4 questionnaire (Douler Neuropathique 4) dermatological pattern of pain after surgery characteristics of neuropathic pain including numbness, tingling, tingling, electric shock, burning, hyperalgesia, allodynia (pain with a stimulus that It usually does not cause pain (falling asleep and itching)
Exclusion criteria
Exclusion criteria: contraindications for BoNT (eg, myasthenia gravis or other neuromuscular junction diseases) hypersensitivity to the BoNT coagulation disorders other painful conditions History of previous BoNT treatment Concomitant use of pain medication is allowed, provided that the dose has been stable for at least 1 month before enrollment and will remain stable during the study. opioid usage
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Primary outcome measures will include changes in pain intensity. Timepoint: pain intensity in the last 24 hours using NRS (0=no pain, 100=unbearable pain) at 2, 4, 8 and 12 weeks after injection. Method of measurement: numeric rating scale (NRS). | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome measures will include changes in quality of life. Timepoint: quality of life at 2, 4, 8, and 12 weeks after injection using the SF36 questionnaire. Method of measurement: SF-36 questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHossein Majedi Ardakani
Tehran University of Medical Sciences
Outcome results
None listed